Curvebeam Ai Ltd
CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and Australia. The company offers HiRise for bilateral weight bearing CT imaging; LineUP, a bilateral, weight bearing CT imaging of the knees and lower extremities for orthpedic practices; pedCAT Premium and pedCAT for imaging of the foot … Read more
Curvebeam Ai Ltd (CVB) - Net Assets
Latest net assets as of June 2025: AU$35.11 Million AUD
Based on the latest financial reports, Curvebeam Ai Ltd (CVB) has net assets worth AU$35.11 Million AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$60.98 Million) and total liabilities (AU$25.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$35.11 Million |
| % of Total Assets | 57.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Curvebeam Ai Ltd - Net Assets Trend (2021–2025)
This chart illustrates how Curvebeam Ai Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Curvebeam Ai Ltd (2021–2025)
The table below shows the annual net assets of Curvebeam Ai Ltd from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$35.11 Million | -9.79% |
| 2024-06-30 | AU$38.92 Million | +180.91% |
| 2023-06-30 | AU$-48.10 Million | -- |
| 2022-06-30 | AU$0.00 | -- |
| 2021-06-30 | AU$0.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Curvebeam Ai Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10276129000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$136.65 Million | 389.21% |
| Other Components | AU$1.22 Million | 3.47% |
| Total Equity | AU$35.11 Million | 100.00% |
Curvebeam Ai Ltd Competitors by Market Cap
The table below lists competitors of Curvebeam Ai Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
S. Khonkaen Foods Public Company Limited
BK:SORKON
|
$11.44 Million |
|
Paz Oil
TA:PZOL
|
$11.44 Million |
|
Hurum Co. Ltd.
KQ:353190
|
$11.45 Million |
|
Avant Technologies Inc.
OTCQB:AVAI
|
$11.45 Million |
|
Array Inc
TWO:3664
|
$11.43 Million |
|
Merck Tbk
JK:MERK
|
$11.43 Million |
|
Twenty-Four Con & Supply PCL
BK:24CS
|
$11.43 Million |
|
Sat Nusapersada Tbk
JK:PTSN
|
$11.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Curvebeam Ai Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 38,919,609 to 35,110,320, a change of -3,809,289 (-9.8%).
- Net loss of 16,842,750 reduced equity.
- Share repurchases of 11,584,410 reduced equity.
- Other factors increased equity by 24,617,871.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-16.84 Million | -47.97% |
| Share Repurchases | AU$11.58 Million | -32.99% |
| Other Changes | AU$24.62 Million | +70.12% |
| Total Change | AU$- | -9.79% |
Book Value vs Market Value Analysis
This analysis compares Curvebeam Ai Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | AU$0.00 | AU$0.06 | x |
| 2022-06-30 | AU$0.00 | AU$0.06 | x |
| 2023-06-30 | AU$-0.69 | AU$0.06 | x |
| 2024-06-30 | AU$0.12 | AU$0.06 | x |
| 2025-06-30 | AU$0.09 | AU$0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Curvebeam Ai Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -139.24%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.74x
- Recent ROE (-47.97%) is below the historical average (-21.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -93.73% | 0.00x | 0.00x | AU$-6.75 Million |
| 2022 | 0.00% | -511.06% | 0.00x | 0.00x | AU$-8.54 Million |
| 2023 | 0.00% | -646.15% | 0.13x | 0.00x | AU$-47.24 Million |
| 2024 | -59.36% | -353.94% | 0.10x | 1.63x | AU$-26.99 Million |
| 2025 | -47.97% | -139.24% | 0.20x | 1.74x | AU$-20.35 Million |
Industry Comparison
This section compares Curvebeam Ai Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $14,750,885
- Average return on equity (ROE) among peers: -315.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Curvebeam Ai Ltd (CVB) | AU$35.11 Million | 0.00% | 0.74x | $11.44 Million |
| 4DMEDICAL Ltd (4DX) | $926.64K | -85.93% | 0.18x | $1.03 Billion |
| Adherium Ltd (ADR) | $34.53 Million | -3.63% | 0.08x | $2.37 Million |
| Aroa Biosurgery Ltd (ARX) | $-22.65 Million | 0.00% | 0.00x | $92.74 Million |
| Atomo Diagnostics Ltd (AT1) | $34.48 Million | -26.73% | 0.05x | $8.96 Million |
| Control Bionics Ltd (CBL) | $6.09 Million | -15.97% | 0.04x | $4.98 Million |
| Cardiex Ltd (CDX) | $3.03 Million | -101.61% | 0.73x | $4.25 Million |
| Compumedics Ltd (CMP) | $9.21 Million | -30.70% | 1.16x | $13.08 Million |
| Cochlear Ltd (COH) | $75.42 Million | 53.19% | 1.13x | $7.01 Billion |
| Cleo Diagnostics Ltd (COV) | $5.83 Million | -68.54% | 0.19x | $23.47 Million |
| Conneqt Health Limited (CQT) | $633.50K | -2871.98% | 13.72x | $4.66 Million |